[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367085-105":59,"doc-detail-367085-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","injecting-hope-the-potential-of-intratumoral-immunotherapy-for-locally-advanced-and-metastatic-cancer","Injecting hope - the potential of intratumoral immunotherapy for locally advanced and metastatic cancer","","Despite major advances, locally advanced and metastatic cancers remain among the most serious health challenges, and many anticancer strategies fail to deliver durable survival benefits. Systemic immunotherapies can cause frequent adverse effects, driving treatment modifications or discontinuation. Intratumoral immunotherapy is presented as a promising alternative with reduced side effects, cost, and systemic toxicity. This review surveys current intratumoral approaches, their integration with other modalities, and outlines future directions for combination regimens targeting multiple cancer hallmarks.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/injecting-hope-the-potential-of-intratumoral-immunotherapy-for-locally-advanced-and-metastatic-cancer/367085/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/injecting-hope-the-potential-of-intratumoral-immunotherapy-for-locally-advanced-and-metastatic-cancer/367085.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do advanced cancers still pose a major treatment challenge?","Question",{"text":112,"@type":113},"Advanced cancers remain difficult to control, and existing anticancer strategies often do not achieve satisfactory long-term outcomes and survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitation of systemic immunotherapy motivates intratumoral approaches?",{"text":117,"@type":113},"Many systemic immunotherapies cause frequent side effects, leading to treatment changes, discontinuation, or severe outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review aim to cover about intratumoral immunotherapy?",{"text":121,"@type":113},"It provides an overview of intratumoral immunotherapeutic approaches for locally advanced and metastatic cancers, discusses how intratumoral administration can be combined with other modalities, and highlights recent advances and future directions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367085,1790623427,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Review  \nPUBLISHED 09 January 2025  \nDOI 10.3389/fimmu.2024.1479483  \nOPEN ACCESS  \nEDITED BY  \nElena Voronov,  \nBen-Gurion University of the Negev, Israel  \nREVIEWED BY  \nNamrata Gautam,  \nMoffitt Cancer Center, United States Tommaso Virgilio,  \nInstitute for Research in Biomedicine (IRB), Switzerland  \n*CORRESPONDENCE  \nMilan Jakubek  \n [Milan.Jakubek@lf1.cuni.cz](Milan.Jakubek@lf1.cuni.cz)  \nRECEIVED 12 August 2024  \nACCEPTED 17 December 2024  \nPUBLISHED 09 January 2025  \nCITATION  \nSkalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M, Kejík Z, Martasek P, Pacak K and Jakubek M (2025) Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.  \nFront. Immunol. 15:1479483 .  \ndoi: 10.3389/fimmu.2024.1479483  \nCOPYRIGHT  \n© 2025 Skalickova, Hadrava Vanova, Uher, Leischner Fialova, Petrlakova, Masarik, Kejík, Martasek, Pacak and Jakubek. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nInjecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer  \nMarketa Skalickova 1,2, Katerina Hadrava Vanova 3, Ondrej Uher 3,  \nJindriska Leischner Fialova 1,2,4, Katerina Petrlakova 4, Michal Masarik 1,2,4,5, Zdeněk Kejík1,2, Pavel Martasek 2, Karel Pacak 3 and Milan Jakubek 1,2*  \n1 BIOCEV, First Faculty of Medicine, Charles University, Vestec, Czechia, 2 Department of Paediatricsand Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czechia, 3Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda,  \nMD, United States, 4 Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia, 5 Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czechia  \nDespite enormous progress, advanced cancers are still one of the most serious medical problems in current society. Although various agents and therapeutic strategies with anticancer activity are known and used, they often fail to achieve satisfactory long-term patient outcomes and survival. Recently, immunotherapy has shown success in patients by harnessing important interactions between the immune system and cancer. However, many of these therapies lead to frequent side effects when administered systemically, prompting treatment modifications or discontinuation or, in severe cases, fatalities. New therapeutic approaches like intratumoral immunotherapy, characterized by reduced side effects, cost, and systemic toxicity, offer promising prospects for future applications in clinical oncology. In the context of locally advanced or metastatic cancer, combining diverse immunotherapeutic and other treatment strategies targeting multiple cancer hallmarks appears crucial. Such combination therapies hold promise for improving patient outcomes and survival and for promoting a sustained systemic response. This review aims to provide a current overview of immunotherapeutic approaches, specifically focusing on the intratumoral administration of drugs inpatients with locally advanced and metastatic cancers. It also explores the integration of intratumoral administration with other modalities to maximize therapeutic response. Additionally, the review summarizes recent advances in intratumoral immunotherapy and discusses novel therapeutic approaches, outlining future directions in the field.  \nKEYWORDS  \ncancer, immunotherapy, intratumoral, combination therapy, advanced and metastat","cbCaiepv0SZDl89i","https://ap.wps.com/l/cbCaiepv0SZDl89i","pdf",2823245,"English","# Introduction\n## Intratumoral immunotherapy as a promising approach\n# Goals and scope of the review\n## Integration with other modalities\n# Current immunotherapeutic approaches\n## Combination strategies and future directions","[{\"question\":\"Why do advanced cancers still pose a major treatment challenge?\",\"answer\":\"Advanced cancers remain difficult to control, and existing anticancer strategies often do not achieve satisfactory long-term outcomes and survival.\"},{\"question\":\"What limitation of systemic immunotherapy motivates intratumoral approaches?\",\"answer\":\"Many systemic immunotherapies cause frequent side effects, leading to treatment changes, discontinuation, or severe outcomes.\"},{\"question\":\"What does the review aim to cover about intratumoral immunotherapy?\",\"answer\":\"It provides an overview of intratumoral immunotherapeutic approaches for locally advanced and metastatic cancers, discusses how intratumoral administration can be combined with other modalities, and highlights recent advances and future directions.\"}]","Injecting hope - the potential of intratumoral immunotherapy for locally advanced and metastatic cancer | PDF",1790169206]